Clinical outcomes of different regimens of intravitreal Conbercept for the treatment of choroidal neovascularization secondary to pathological myopia.
Best corrected visual acuity
Central retinal thickness
Choroidal neovascularization
Conbercept
Pathological myopia
Journal
International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
03
08
2022
accepted:
19
02
2023
medline:
18
9
2023
pubmed:
10
8
2023
entrez:
10
8
2023
Statut:
ppublish
Résumé
To assess the clinical outcomes of two intravitreal injection regimens of Conbercept used to treat choroidal neovascularization secondary to pathological myopia (PM-CNV). A total of 72 eyes of 72 patients were treated: 39 eyes received a single injection followed by treatment pro re nata (1 + PRN); 33 eyes first received 3 consecutive monthly injections (3 + PRN) then followed by PRN. After initial injection, patients were followed up for 12 months. The mean age of 72 patients was 45.3 ± 5.1 years, with the mean diopter of -10.62 ± 3.24D. The best corrected visual acuity (BCVA) was 0.86 ± 0.23 LogMAR with 1 + PRN and 0.90 ± 0.19 LogMAR with 3 + PRN at baseline (P = 0.422), 0.36 ± 0.07 and 0.33 ± 0.05 LogMAR at month 3 (P = 0.026); and 0.33 ± 0.03 and 0.32 ± 0.02 LogMAR at month 12 (P = 0.096). The central retinal thickness (CRT) was 333.5 ± 22.7 μm with 1 + PRN and 341.2 ± 20.9 μm with 3 + PRN at baseline (P = 0.139), 281.53 ± 10.28 and 273.15 ± 13.24 μm at month 3 (P = 0.004); 266.83 ± 8.14 and 264.91 ± 9.27 μm at month 12 (P = 0.350). The number of injections in the 1 + PRN group was significantly lower than that observed in the 3 + PRN group (2.15 ± 1.06 versus 3.36 ± 0.74; P < 0.001). During the follow-up, no serious ocular complications and adverse reactions related to Conbercept and injections occurred. Both injection regimens resulted in similar visual outcomes in PM-CNV patients. The 1 + PRN regimen had fewer injections and might be more suitable in this patient population.
Identifiants
pubmed: 37561252
doi: 10.1007/s10792-023-02655-9
pii: 10.1007/s10792-023-02655-9
doi:
Substances chimiques
Angiogenesis Inhibitors
0
KH902 fusion protein
1P05PW62F3
Vascular Endothelial Growth Factor A
0
Recombinant Fusion Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3445-3452Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Baird PN, Saw SM, Lanca C et al (2020) Myopia. Nat Rev Dis Primers 6(1):99
doi: 10.1038/s41572-020-00231-4
pubmed: 33328468
Xie J, Chen Q, Yu J et al (2020) Morphologic features of myopic choroidal neovascularization in pathologic myopia on swept-source optical coherence tomography. Front Med (Lausanne) 7:615902
doi: 10.3389/fmed.2020.615902
pubmed: 33425961
Williams KM, Bertelsen G, Cumberland P et al (2015) Increasing prevalence of myopia in Europe and the impact of education. Ophthalmology 122(7):1489–1497
doi: 10.1016/j.ophtha.2015.03.018
pubmed: 25983215
Coco-Martin RM, Belani-Raju M, de la Fuente-Gomez D, SanabriaI MR, Fernández (2021) Progression of myopic maculopathy in a Caucasian cohort of highly myopic patients with long follow-up: a multistate analysis. Graefes Arch Clin Exp Ophthalmol 259(1):81–92
doi: 10.1007/s00417-020-04795-5
pubmed: 32564136
Fang Y, Yokoi T, Nagaoka N et al (2018) Progression of myopic maculopathy during 18-year follow-up. Ophthalmology 125(6):863–877
doi: 10.1016/j.ophtha.2017.12.005
pubmed: 29371011
Chan NS, Teo K, Cheung CM (2016) Epidemiology and diagnosis of myopic choroidal neovascularization in Asia. Eye Contact Lens 42(1):48–55
doi: 10.1097/ICL.0000000000000201
pubmed: 26448447
Isildak H, Schwartz SG, Flynn HW (2018) Pharmacotherapy of myopic choroidal neovascularization. Curr Pharm Des 24(41):4853–4859
doi: 10.2174/1381612825666190124102641
pubmed: 30674251
Wang EYC (2013) Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis. Retina 33(7):1375–1392
doi: 10.1097/IAE.0b013e31827d260a
pubmed: 23514793
Kung YH, Wu, Huang YH (2014) One-year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization. Acta Ophthalmol 92(8):e615–e620
doi: 10.1111/aos.12457
pubmed: 24924911
Calvo-González C, Reche-Frutos J, Fernández-Vigo JI, Sáenz-Francés F, Fernández-PérezJ C, García-Feijóo (2017) Long-term outcomes of two different initial dosing regimens of intravitreal Ranibizumab used to treat myopic choroidal neovascularization. Ophthalmologica 238(4):196–204
doi: 10.1159/000478030
pubmed: 28881344
Ikuno Y, Ohno-Matsui K, Wong TY et al (2015) Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study. Ophthalmology 122(6):1220–1227
doi: 10.1016/j.ophtha.2015.01.025
pubmed: 25745875
Yan M, Huang Z, Lian HY, SongX YP, Chen (2019) Conbercept for treatment of choroidal neovascularization secondary to pathologic myopia. Acta Ophthalmol 97(5):e813–e814
doi: 10.1111/aos.13632
pubmed: 30187680
Liu K, Song Y, Xu G et al (2019) Conbercept for treatment of neovascular age-related macular degeneration: results of the randomized Phase 3 PHOENIX Study. Am J Ophthalmol 197:156–167
doi: 10.1016/j.ajo.2018.08.026
pubmed: 30148987
Liu K, Wang H, He W et al (2022) Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. Br J Ophthalmol 106(10):1436–1443
Gao L, Liu J, Zhang P, MaH J, Wang (2020) Clinical outcomes of 1 + PRN and 3 + Q3M regimens of intravitreal conbercept injection for exudative age-related macular degeneration. Sci Rep 10(1):8010
doi: 10.1038/s41598-020-65000-5
pubmed: 32409739
pmcid: 7224199
Querques G, Srour M, Massamba N, Georges A, Ben Moussa N, Rafaeli O, Souied EH (2013) Functional characterization and multimodal imaging of treatment-naive “quiescent” choroidal neovascularization. Invest Ophthalmol Vis Sci 54(10):6886–6892
doi: 10.1167/iovs.13-11665
pubmed: 24084095
Ohno-Matsui K, Ikuno Y, Lai TYY, Gemmy Cheung CM (2018) Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia. Prog Retin Eye Res 63:92–106
doi: 10.1016/j.preteyeres.2017.10.005
pubmed: 29111299
Wong TY, Ferreira A, Hughes R, CarterP G, Mitchell (2014) Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol 157(1):9-25.e12
doi: 10.1016/j.ajo.2013.08.010
pubmed: 24099276
Nie X, Wang Y, YiY H, Qiao (2021) Intravitreal conbercept for choroidal neovascularisation secondary to pathological myopia in a real-world setting in China : Intravitreal conbercept was safe and effective in treating myopic choroidal neovascularization. BMC Ophthalmol 21(1):116
doi: 10.1186/s12886-021-01877-8
pubmed: 33663431
pmcid: 7934258
Chen C, Yan M, Huang Z, Song YP (2020) The evaluation of a two-year outcome of intravitreal conbercept versus Ranibizumab for pathological myopic choroidal neovascularization. Curr Eye Res 45(11):1415–1421
doi: 10.1080/02713683.2020.1742357
pubmed: 32191134
Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, Reeves BC (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet (London, England) 382(9900):1258–1267
doi: 10.1016/S0140-6736(13)61501-9
pubmed: 23870813
Chen HXJNC (2009) Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 6(8):465–477
doi: 10.1038/nrclinonc.2009.94
pubmed: 19581909
Keane PA, Liakopoulos S, Chang KT, Heussen FM, Ongchin SC, Walsh AC, Sadda SR (2008) Comparison of the optical coherence tomographic features of choroidal neovascular membranes in pathological myopia versus age-related macular degeneration, using quantitative subanalysis. Br J Ophthalmol 92(8):1081–1085
doi: 10.1136/bjo.2008.138891
pubmed: 18586903
Lu H, Yue T, Liu N et al (2021) Efficacy of Conbercept in the treatment of choroidal neovascularization secondary to pathologic myopia. Front Med (Lausanne) 8:720804
doi: 10.3389/fmed.2021.720804
pubmed: 34746171
Maloney MH, Schilz SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ (2019) Risk of systemic adverse events associated with intravitreal anti-VEGF therapy for diabetic macular edema in routine clinical practice. Ophthalmology 126(7):1007–1015
doi: 10.1016/j.ophtha.2018.09.040
pubmed: 30292542
Ikuno Y (2017) Overview of the complications of high myopia. Retina 37(12):2347–2351
doi: 10.1097/IAE.0000000000001489
pubmed: 28590964
Wolf S, Balciuniene VJ, Laganovska G et al (2014) RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 121(3):682–92.e2
doi: 10.1016/j.ophtha.2013.10.023
pubmed: 24326106
Lu XXS (2015) Profile of conbercept in the treatment of neovascular age-related macular degeneration. Drug Des Devel Ther 9:2311–2320
pubmed: 25960634
pmcid: 4410828
Liu H, Ma Y, Xu HC, Huang LY, Zhai LY, Zhang XR (2020) Updates on the management of ocular vasculopathies with VEGF inhibitor Conbercept. Curr Eye Res 45(12):1467–1476
doi: 10.1080/02713683.2020.1781193
pubmed: 32631094